Remdesivir in COVID-19 Patients with Impaired Renal Function

Sanna Gevers¹, Jan Welink¹, Cees van Nieuwkoop^{1

2}

Affiliations

¹ Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
² Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands.

Sanna Gevers et al. J Am Soc Nephrol. 2021.

. 2021 Feb 1;32(2):518-519.

doi: 10.1681/ASN.2020101535. Epub 2021 Jan 21.

Sanna Gevers¹, Jan Welink¹, Cees van Nieuwkoop^{1

2}

¹ Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
² Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands.

No abstract available

Comment on

1. Adamsick ML, Gandhi RG, Bidell MR, Elshaboury RH, Bhattacharyya RP, Kim AY, et al. .: Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol 31: 1384–1386, 2020 - PMC - PubMed
1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group Members : Remdesivir for the treatment of Covid-19—Final report. N Engl J Med 383: 1813–1826, 2020. - PMC - PubMed
1. European Medicines Agency : Summary on compassionate use. Remdesivir Gilead, 2020. Available at: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-r.... Accessed October 16, 2020
1. Jorgensen SCJ, Kebriaei R, Dresser LD: Remdesivir: Review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40: 659–671, 2020 - PMC - PubMed
1. Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, et al. .; COVID 19 INMI Study Group: Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75: 2977–2980, 2020 - PMC - PubMed